OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost purchased 125,000 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were purchased at an average cost of $1.36 per share, with a total value of $170,000.00. Following the completion of the transaction, the chief executive officer now owns 214,001,448 shares of the company's stock, valued at approximately $291,041,969.28. The trade was a 0.06 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Tuesday, April 8th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $185,000.00.
- On Tuesday, April 1st, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.65 per share, with a total value of $165,000.00.
- On Friday, March 28th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.70 per share, with a total value of $255,000.00.
- On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.74 per share, for a total transaction of $348,000.00.
- On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was acquired at an average price of $1.71 per share, with a total value of $115,312.14.
- On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, for a total transaction of $69,879.39.
- On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were bought at an average price of $1.47 per share, for a total transaction of $220,500.00.
- On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.48 per share, for a total transaction of $740,000.00.
OPKO Health Stock Down 8.7 %
NASDAQ:OPK opened at $1.36 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company's fifty day moving average price is $1.69 and its 200-day moving average price is $1.58. OPKO Health, Inc. has a 1-year low of $1.15 and a 1-year high of $2.04. The firm has a market capitalization of $913.31 million, a P/E ratio of -7.16 and a beta of 1.78.
OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.
Institutional Trading of OPKO Health
Several hedge funds and other institutional investors have recently bought and sold shares of OPK. FMR LLC lifted its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 11,089 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in OPKO Health in the third quarter valued at $45,000. Cibc World Markets Corp purchased a new stake in shares of OPKO Health during the 4th quarter worth about $45,000. Finally, Zacks Investment Management purchased a new stake in shares of OPKO Health during the 4th quarter worth about $49,000. 64.63% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on OPK shares. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. Barrington Research reiterated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. Finally, HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Monday.
Read Our Latest Analysis on OPK
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
